Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.32 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16006823 | 0.89 | NMT1 (0.36) | KEAP1NFE2L2TSHRKMT2AALDH1A1 | |
| SCHEMBL16006406 | 0.88 | CCR4 (0.36) | KEAP1NFE2L2TSHRKMT2AABL1 | |
| SCHEMBL16006826 | 0.87 | CA1 (0.37) | TSHRKDM4ECA12CA1CA2 | |
| SCHEMBL19788825 | 0.86 | CHRM4 (0.31) | TSHRKMT2AKDM4ESMN1; SMN2CHRM4 | |
| SCHEMBL16006818 | 0.86 | CCR4 (0.41) | KMT2AALDH1A1KDM4ESMN1; SMN2BRD4 | |
| SCHEMBL24997652 | 0.86 | L3MBTL1 (0.38) | TSHRKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16006420 | 0.84 | PTGS2 (0.35) | TSHRCHRM4BRD4CREBBPCECR2 | |
| SCHEMBL16157996 | 0.82 | CA2 (0.37) | SMN1; SMN2CA1CA2PTGS2PTGS1 | |
| SCHEMBL16006656 | 0.79 | CA1 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL16006409 | 0.78 | KEAP1 (0.42) | KEAP1NFE2L2KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262990-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-2961742-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2014134566-A2 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | KEAP1 2233/4885NFE2L2 3042/4885TSHR 4738/4885 |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | KEAP1 2091/4885NFE2L2 2943/4885TSHR 4662/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | KEAP1 2091/4885NFE2L2 2943/4885TSHR 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.